Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Jelinek, Jaroslav ^a   Gharibyan, Vazganush ^a   Estecio, Marcos R H ^a   Kondo, Kimie ^a   He, Rong ^a   Chung, Woonbok ^a   Lu, Yue ^a   Zhang, Nianxiang ^a   Liang, Shoudan ^a   Kantarjian, Hagop M ^a   Cortes, Jorge E ^a   Issa, Jean Pierre J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CADHERIN; CADHERIN H; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DIHYDROPYRIMIDINASE; IMATINIB; LIM PROTEIN; NUCLEOPHOSMIN; NUCLEOPHOSMIN 2; PROTEIN PDLIM4; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2 EPSILON; UNCLASSIFIED DRUG; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MYELOPROLIFERATIVE DISORDER; PERIPHERAL BLOOD MONONUCLEAR CELL; PROMOTER REGION; PROTEIN FUNCTION; PYROSEQUENCING; SURVIVAL TIME; CANCER STAGING; DISEASE COURSE; DNA MICROARRAY; DNA SEQUENCE; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN GENOME; MIDDLE AGED; MULTIVARIATE ANALYSIS; SURVIVAL; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR GENE;

ADOLESCENT; ADULT; AGED; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, NEOPLASM; GENOME, HUMAN; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PIPERAZINES; PYRIMIDINES; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960101630     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022110     Document Type: Article

References (51)

1. Toyota M, Issa JP, (2005) Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 32: 521-530.
2. Kroeger H, Jelinek J, Estecio MR, He R, Kondo K, et al. (2008) Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112: 1366-1373.
3. Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, et al. (2008) Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 22: 1529-1538.
4. Rush LJ, Raval A, Funchain P, Johnson AJ, Smith L, et al. (2004) Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res 64: 2424-2433.
5. Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, et al. (2006) CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res 66: 653-658.
6. Kanduri M, Cahill N, Goransson H, Enstrom C, Ryan F, et al. (2010) Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood 115: 296-305.
7. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, et al. (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113: 1315-1325.
8. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, et al. (2010) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28: 605-613.
9. Daley GQ, Baltimore D, (1988) Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A 85: 9312-9316.
10. Quintas-Cardama A, Kantarjian H, Cortes J, (2009) Imatinib and beyond-exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 6: 535-543.
11. Nelkin BD, Przepiorka D, Burke PJ, Thomas ED, Baylin SB, (1991) Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia. Blood 77: 2431-2434.
12. Issa JP, Zehnbauer BA, Civin CI, Collector MI, Sharkis SJ, et al. (1996) The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res 56: 973-977.
13. Issa JP, Zehnbauer BA, Kaufmann SH, Biel MA, Baylin SB, (1997) HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res 57: 1678-1681.
14. Nguyen TT, Mohrbacher AF, Tsai YC, Groffen J, Heisterkamp N, et al. (2000) Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. Blood 95: 2990-2992.
15. Roman-Gomez J, Castillejo JA, Jimenez A, Cervantes F, Boque C, et al. (2003) Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. J Clin Oncol 21: 1472-1479.
16. Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, et al. (2007) Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res 13: 5048-5055.
17. Zion M, Ben-Yehuda D, Avraham A, Cohen O, Wetzler M, et al. (1994) Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci U S A 91: 10722-10726.
18. Pehlivan M, Sercan Z, Sercan HO, (2009) sFRP1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia. Leuk Res 33: 1062-1067.
19. Avramouli A, Tsochas S, Mandala E, Katodritou E, Ioannou M, et al. (2009) Methylation status of RASSF1A in patients with chronic myeloid leukemia. Leuk Res 33: 1130-1132.
20. Dunwell T, Hesson L, Rauch TA, Wang L, Clark RE, et al. (2010) A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol Cancer 9: 44.
21. Jelinek J, Mannari R, Issa J-P, (2004) Identification of 41 novel promoter-associated CpG islands methylated in leukemias [Meeting Abstract]. Blood 104: 319a.
22. Jelinek J, Prchal JT, Issa JP, (2003) Methylation at CpG islands of tumor-associated genes in polycythemia vera [Meeting Abstract]. Blood 102: 660A-660A.
23. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, et al. (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57: 837-841.
24. Lozzio CB, Lozzio BB, (1975) Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45: 321-334.
25. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, et al. (1999) Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 59: 2307-2312.
26. Estecio MR, Yan PS, Ibrahim AE, Tellez CS, Shen L, et al. (2007) High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res 17: 1529-1536.
27. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, et al. (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125: 301-313.
28. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, et al. (2004) A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 101: 6062-6067.
29. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, et al. (2005) Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23: 3948-3956.
30. Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, et al. (2006) DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 38: 1378-1385.
31. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, et al. (2004) A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 32: e38.
32. Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, et al. (2007) RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res 67: 1997-2005.
33. Vanaja DK, Grossmann ME, Cheville JC, Gazi MH, Gong A, et al. (2009) PDLIM4, an actin binding protein, suppresses prostate cancer cell growth. Cancer Invest 27: 264-272.
34. Zhang Y, Tu Y, Zhao J, Chen K, Wu C, (2009) Reversion-induced LIM interaction with Src reveals a novel Src inactivation cycle. J Cell Biol 184: 785-792.
35. Chung W, Kwabi-Addo B, Ittmann M, Jelinek J, Shen L, et al. (2008) Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One 3: e2079.
36. Herman JG, Jen J, Merlo A, Baylin SB, (1996) Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 56: 722-727.
37. Inoue A, Aoki F, (2010) Role of the nucleoplasmin 2 C-terminal domain in the formation of nucleolus-like bodies in mouse oocytes. Faseb J 24: 485-494.
38. Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, et al. (2009) Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res 19: 1462-1470.
39. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, et al. (2007) Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 9: R57.
40. Tellez CS, Shen L, Estecio MRH, Jelinek J, Gershenwald JE, et al. (2009) CpG island methylation profiling in human melanoma cell lines. Melanoma Research 19: 146-155.
41. Kondo Y, Shen L, Suzuki S, Kurokawa T, Masuko K, et al. (2007) Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 37: 974-983.
42. Widschwendter A, Muller HM, Fiegl H, Ivarsson L, Wiedemair A, et al. (2004) DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res 10: 565-571.
43. Nie X, Zhang B, Li X, Xiang J, Xiao B, et al. (2003) Cloning, expression, and mutation analysis of NOR1, a novel human gene down-regulated in HNE1 nasopharyngeal carcinoma cell line. J Cancer Res Clin Oncol 129: 410-414.
44. Kobayashi Y, Shibusawa A, Saito H, Ohshiro N, Ohbayashi M, et al. (2005) Isolation and functional characterization of a novel organic solute carrier protein, hOSCP1. J Biol Chem 280: 32332-32339.
45. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, et al. (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96: 8681-8686.
46. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP, (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141-196.
47. Estecio MR, Gharibyan V, Shen L, Ibrahim AE, Doshi K, et al. (2007) LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS ONE 2: e399.
48. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, et al. (2005) Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24: 7213-7223.
49. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, et al. (2008) Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia. Leuk Res 32: 487-490.
50. Jabbour E, Cortes J, Kantarjian H, (2009) Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 4: 3-10.
51. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'Brien S, et al. (2007) Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109: 899-906.